The Case for Clinical Trials with Novel GABAergic Drugs in Diabetes Mellitus and Obesity
Open Access
Abstract
Obesity and diabetes mellitus have become the surprising menaces of relative economic well-being worldwide. Gamma amino butyric acid (GABA) has a prominent role in the control of blood glucose, energy homeostasis as well as food intake at several levels of regulation. The effects of GABA in the body are exerted through ionotropic GABAA and metabotropic GABAB receptors. This treatise will focus on the pharmacologic targeting of GABAA receptors to reap beneficial therapeutic effects in diabetes mellitus and obesity. A new crop of drugs selectively targeting GABAA receptors has been under investigation for efficacy in stroke recovery and cognitive deficits associated with schizophrenia. Although these trials have produced mixed outcomes the compounds are safe to use in humans. Preclinical evidence is summarized here to support the rationale of testing some of these compounds in diabetic patients receiving insulin in order to achieve better control of blood glucose levels and to combat the decline of cognitive performance. Potential therapeutic benefits could be achieved (i) By resetting the hypoglycemic counter-regulatory response; (ii) Through trophic actions on pancreatic islets, (iii) By the mobilization of antioxidant defence mechanisms in the brain. Furthermore, preclinical proof-of-concept work, as well as clinical trials that apply the novel GABAA compounds in eating disorders, e.g., olanzapine-induced weight-gain, also appear warranted.Keywords
This publication has 132 references indexed in Scilit:
- Allen Brain Atlas: an integrated spatio-temporal portal for exploring the central nervous systemNucleic Acids Research, 2012
- Anxioselective anxiolytics: on a quest for the Holy GrailTrends in Pharmacological Sciences, 2012
- Pentameric ligand-gated ion channel ELIC is activated by GABA and modulated by benzodiazepinesProceedings of the National Academy of Sciences, 2012
- γ-Aminobutyric acid (GABA) signalling in human pancreatic islets is altered in type 2 diabetesDiabetologia, 2012
- Extrasynaptic GABAA Receptors: Their Function in the CNS and Implications for DiseaseNeuron, 2012
- A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with SchizophreniaBiological Psychiatry, 2011
- Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after strokeNature, 2010
- Six new loci associated with body mass index highlight a neuronal influence on body weight regulationNature Genetics, 2008
- Mitochondrial dysfunction and oxidative stress in neurodegenerative diseasesNature, 2006
- Variations on an inhibitory theme: phasic and tonic activation of GABAA receptorsNature Reviews Neuroscience, 2005